A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

675 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic alopecia (AGA) subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Androgenetic Alopecia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

male pattern baldness SM04554 AGA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Topical SM04554 0.15% solution

Topical SM04554 0.15% solution, once daily for up to 48 weeks

Group Type EXPERIMENTAL

Topical SM04554 solution

Intervention Type DRUG

Study medication application will be performed by the individual subject at approximately the same time each day.

Topical SM04554 0.25% solution

Topical SM04554 0.25% solution, once daily for up to 48 weeks

Group Type EXPERIMENTAL

Topical SM04554 solution

Intervention Type DRUG

Study medication application will be performed by the individual subject at approximately the same time each day.

Vehicle

Topical vehicle solution, once daily for up to 48 weeks

Group Type PLACEBO_COMPARATOR

Topical vehicle solution

Intervention Type DRUG

Vehicle solution application will be performed by the individual subject at approximately the same time each day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Topical SM04554 solution

Study medication application will be performed by the individual subject at approximately the same time each day.

Intervention Type DRUG

Topical SM04554 solution

Study medication application will be performed by the individual subject at approximately the same time each day.

Intervention Type DRUG

Topical vehicle solution

Vehicle solution application will be performed by the individual subject at approximately the same time each day.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Being a Turkish citizen
* Clinical diagnosis of AGA with Norwood-Hamilton Classification score of 3V or 4
* Willing to inform females, with whom they may interact, that they are using a topical investigational product and direct contact should be avoided as potential harm to a fetus is unknown
* Willing and able to attend all study visits
* Willing to maintain the same hair style and length as at the study start for the duration of the study
* Willing to not use semi-permanent hair products (e.g., color, texturizers, relaxers) for the duration of the study; daily styling products (e.g., hair gel, mousse, styling spray) will be allowed on non-study visit days
* Willing to use mild non-medicated shampoo and conditioner for the duration of the study
* Able to read and understand Turkish
* Ability to comprehend and willing to sign an informed consent form

Exclusion Criteria

* Males who are sexually active, and have a partner who is capable of becoming pregnant, if neither has had surgery to become sterilized, and/or who are not willing to use condom or whose partner is not using a highly effective method of birth control that includes double barrier, intrauterine device, or hormonal contraceptive combined with single barrier, or abstinence during the study treatment period until 90 days post last dose of study medication
* Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
* Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
* History of surgical correction (e.g., hair transplantation, scalp reduction) of hair loss on the scalp
* Previous exposure to SM04554
* Use of any products (e.g., finasteride, minoxidil, platelet rich plasma, biotin) or devices (e.g., laser light therapy) purported to promote scalp hair growth within 24 weeks prior to the start of the study
* Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to the start of the study
* Use of medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within 12 weeks prior to the start of the study
* Current use of an occlusive wig, hair extensions, or hair weaves
* History of hypersensitivity or allergies to any ingredient of the study medication
* Participation in any other investigational drug or medical device trial, which includes or included administration of an investigational study medication or medical device, within 30 days or 5 half-lives of the investigational agent, whichever is longer, prior to the start of the study
* Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30 days prior to the start of the study
* Use of medicated shampoo or conditioner (medicated shampoo and conditioner refers to any prescription shampoo or conditioner as well as any over-the-counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth) within 30 days prior to the start of the study
* Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site
* Subjects employed by Samumed, LLC or Samumed Turkey, or any of its affiliates or development partners (i.e., an employee, temporary contract worker, or designee) responsible for the conduct of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yusuf Yazici, M.D.

Role: STUDY_DIRECTOR

Biosplice Therapeutics, Inc.

Review additional registry numbers or institutional identifiers associated with this trial.

SM04554-AGA-05

Identifier Type: -

Identifier Source: org_study_id

A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Topical SM04554 0.15% solution

Topical SM04554 solution

Topical SM04554 0.25% solution

Topical SM04554 solution

Vehicle

Topical vehicle solution

Interventions

Topical SM04554 solution

Topical SM04554 solution

Topical vehicle solution

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Biosplice Therapeutics, Inc.

Responsible Party

Principal Investigators

Yusuf Yazici, M.D.

Locations

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site 1

Research Site 2

Countries

Other Identifiers

SM04554-AGA-05